What is it about?
Drug resistant tuberculosis is challenging to diagnose and treat. Identifying drug resistance early allows us to treat the disease and ensure cure. In this study we have analyzed the specific genetic mutations responsible for resistance to Isoniazid, a first line drug in treatment of tuberculosis and treatment outcome in relation to the genetic mutations.
Featured Image
Why is it important?
Isoniazid mono resistance is among rise in drug resistant tuberculosis. Our study shows that identifying the specific mutations causing isoniazid resistance by using Line probe assays shortens the time for diagnosis. In spite of relatively complicated and heterogeneous treatment regimens, patients with Isoniazid mono resistant tuberculosis had a high treatment success rate.
Perspectives
As the drug resistant tuberculosis is on the rise, more data regarding the resistance conferring mutations and the geographic variability is needed in planning appropriate treatment regimens to assure better outcome of the disease. I hope my study could be of use to other researchers who are working on drug resistant tuberculosis.
Rajyalakshmi Gurram
Andhra Medical College
Read the Original
This page is a summary of: Mutation analysis and treatment outcomes of Isoniazid monoresistant tuberculosis, September 2020, European Respiratory Society (ERS),
DOI: 10.1183/13993003.congress-2020.464.
You can read the full text:
Contributors
The following have contributed to this page
